Database
Announced Canadian transactions sized over $1b, as the filing discloses it. 67 transactions.
3 in full, as a subscriber sees them
Every row in the register above is named, with its terms listed and its figures withheld. These three are shown complete.
(Calgary Time) on October 7, 2025 (or if the Meeting is adjourned or postponed, no later than 4:30 p.m.
cash consideration $27.25 (per MEG Share)
consideration form cash and shares
premium to market 30% (its NAV)
price per security $28.18 (per share)
Consideration $8.20B
Opened 07 Oct 2025
BMO Capital Markets (financial advisor); Burnet, Duckworth & Palmer LLP (legal advisor); RBC Capital Markets (financial advisor); Norton Rose Fulbright Canada LLP (legal advisor)
“The Cenovus Transaction provides MEG Shareholders with choice to elect their preferred form of consideration and is to be completed by way of a plan of arrangement under the Business Corporations Act ( Alberta ) where each MEG Shareholder will be entitled to elect to receive: i. $27.25 in cash per MEG Share; or ii.”
“Unlike the Revised Strathcona Offer, the Cenovus Transaction offers MEG Shareholders either the combination of cash and shares, or the option to choose their preferred form of consideration.”
“Third party research notes that Strathcona is "trading at a ~30% premium to its NAV, versus the median E&P in our coverage trades at a discount" 1 and, as of September 12, 2025 , the median target price of Strathcona Shares among equity research analysts covering Strathcona was below the market-observed trading price of Strathcona Shares.”
“Reaffirms Support for the Cenovus Transaction (CNW Group/MEG Energy Corp.) On August 22, 2025 , MEG announced it had entered into an arrangement agreement (the "Arrangement Agreement") with Cenovus Energy Inc. (TSX: CVE ) (NYSE: CVE) ("Cenovus") under which Cenovus will acquire all of the issued and outstanding MEG Shares in a transaction that values MEG at $28.18 per share on a fully prorated basis at Cenovus's closing share price on September 12, 2025 , representing an enterprise value of approximately $8.2 billion , including assumed debt (the "Cenovus Transaction").”
Carriage Hill Properties Acquisition Corp. ("Carriage Hill" or the "Purchaser"), a newly formed entity, established in connection with the transaction, together with the manager CLV Asset Management Inc. confirmed the completion of the previously announced privatization of InterRent Real Estate Investment Trust (TSX: IIP.UN ) ("InterRent" or the "REIT").
cash consideration $13.55 (per unit)
Consideration $4B
BMO Capital Markets (financial advisor); Norton Rose Fulbright Canada LLP (legal advisor); Gowling WLG (Canada) LLP (legal advisor); Scotiabank (financial advisor); Goodmans LLP (legal advisor); Stikeman Elliott LLP (legal advisor); LaBarge Weinstein LLP (legal advisor); Skadden, Arps, Slate, Meagher & Flom LLP (legal advisor)
“Pursuant to the arrangement, Carriage Hill acquired all of the issued and outstanding units of InterRent, other than certain units held by retained interest holders, for cash consideration of $13.55 per unit.”
Apotex Health Corp. (" Apotex " or the " Company ") today announced the pricing of its upsized initial public offering of 54,166,670 common shares of the Company (the " Common Shares ") at a price of $24.00 per Common Share (the " Offering Price "), for gross proceeds of $1,300,000,080 (the " Offering "), following the filing of the Company's final base PREP prospectus (the " Final Prospectus ")…
price per security $22.00 (per Common Share)
price per security $24.00 (per Common Share)
Consideration $1.30B
Goodmans LLP (legal advisor); Stikeman Elliott LLP (legal advisor); Kirkland & Ellis LLP (legal advisor); Skadden, Arps, Slate, Meagher & Flom LLP (legal advisor)
“Assuming an Offering size of approximately $1.3 billion and an Offering Price of $22.00 per Common Share (the midpoint of the Offering Price range), following completion of the Offering, an aggregate of 231,726,671 Common Shares will be issued and outstanding on a non-diluted basis (or 247,662,946 Common Shares on a fully diluted basis) and SK Artemis Holdings, II, LLC and API Investment LP will beneficially hold approximately 54.3% and 14.0% of the Common Shares (on a non-diluted basis), respectively (or 50.6% and 14.0% of the Common Shares (on a non-diluted basis) if the Over-Allotment Optio”
“APOTEX HEALTH CORP. FILES FINAL PROSPECTUS AND ANNOUNCES PRICING OF UPSIZED INITIAL PUBLIC OFFERING Apotex Health Corp. (" Apotex " or the " Company ") today announced the pricing of its upsized initial public offering of 54,166,670 common shares of the Company (the " Common Shares ") at a price of $24.00 per Common Share (the " Offering Price "), for gross proceeds of $1,300,000,080 (the " Offering "), following the filing of the Company's final base PREP prospectus (the " Final Prospectus ") with the securities regulatory authorities in each of the provinces and territories of Canada, the is”
Compiled from public filings, court documents, exchange bulletins and issuer releases. Figures are as disclosed and are not independently verified.
Not financial, investment, legal or tax advice, and not an offer to buy or sell any security. Verify everything before you transact.
The Deal Register · thedealregister.com